Saturday 17 October 2026
Export WVE’s income statement to Excel — free account
WAVE Life Sciences Ltd.
In the quarter to June 2026, revenue fell 73.9%, EPS fell 9.68% and free cash flow fell 17.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.12
0.07
−2.19%
Follow WVE
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | 3 | 3 | 3 | 5 | 5 | 2 | 4 | 2 | 3 |
Altman Z-Score |
15.35 | 13.80 | 0.24 | (3.97) | (3.76) | (6.14) | (10.94) | (4.04) | 2.72 | 11.34 |
P/S ratio |
547.06 | 237.00 | 84.49 | 16.99 | 15.38 | 3.23 | 133.98 | 5.00 | 15.79 | 67.10 |
Altman Z″-Score (non-manufacturers) |
8.29 | 2.04 | (5.42) | (9.18) | (8.66) | (13.50) | (28.05) | (12.47) | (7.05) | 0.83 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | 1.40 | (1.70) | (2.90) | — | — | — | (2.67) | (2.44) |
P/Operating CF |
(44.76) | (40.55) | (37.11) | (4.44) | (9.83) | (23.14) | (14.62) | (17.04) | (39.19) | (84.88) |
P/B ratio |
4.43 | 6.61 | 16.60 | 4.26 | 3.73 | 5.01 | 0.00 | 14.30 | 8.16 | 5.53 |
Price to Tangible BV |
4.43 | 6.61 | 16.60 | 4.26 | 3.73 | 5.01 | 0.00 | 14.30 | 8.16 | 5.53 |
EV/Sales |
409.44 | 200.40 | 72.37 | 7.79 | 6.19 | 0.24 | 109.74 | 3.23 | 13.00 | 53.01 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(14.00) | (9.32) | (45.63) | (0.66) | (1.07) | (0.14) | (3.13) | (18.85) | (9.33) | (12.08) |
EV/FCF |
(11.93) | (7.61) | (31.80) | (0.65) | (1.06) | (0.14) | (3.10) | (17.82) | (9.27) | (12.03) |
Quick Ratio |
12.36 | 7.89 | 1.42 | 1.41 | 1.77 | 2.35 | 1.24 | 1.19 | 2.74 | 6.35 |
Current Ratio |
12.50 | 8.27 | 1.56 | 1.57 | 1.90 | 2.53 | 1.38 | 1.26 | 2.89 | 6.47 |
Net Debt/EBITDA |
2.74 | 1.42 | 1.13 | 0.74 | 1.29 | 1.28 | 0.58 | 3.41 | 2.97 | 2.92 |
Debt/Assets |
0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.02 | 0.06 | 0.06 | 0.07 | 0.17 | 0.02 | 0.54 | 0.35 | 0.09 |
Operating CF/Net income |
0.57 | 0.82 | 0.16 | 0.97 | 0.77 | 0.73 | 0.79 | 0.34 | 1.56 | 0.92 |
Capex/Depreciation |
(7.10) | (9.70) | (2.07) | (0.43) | (0.13) | (0.06) | (0.12) | (0.12) | (0.11) | (0.08) |
| (38.61%) | (74.31%) | (137.73%) | (282.52%) | (204.64%) | (212.09%) | 2,570.05% | 2,106.32% | (77.87%) | (56.16%) | |
| (33.71%) | (58.84%) | (61.39%) | (66.75%) | (53.21%) | (50.28%) | (91.58%) | (27.30%) | (30.94%) | (41.26%) | |
ROIC |
0.00% | (1,284.77%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(37.50%) | (63.88%) | (130.75%) | (186.75%) | (108.47%) | (101.34%) | (365.29%) | (92.74%) | (44.18%) | (38.77%) |
Average Days of Receivables |
0.00 | 93.76 | 253.23 | 456.74 | 545.40 | 0.00 | 0.00 | 67.93 | 4.79 | 10.90 |
Research and Development Expense of Revenue |
3,737.91% | 2,037.22% | 932.62% | 1,097.61% | 652.21% | 297.52% | 3,175.01% | 114.74% | 147.44% | 427.78% |
Selling, General and Administrative Expense of Revenue |
1,464.65% | 692.91% | 274.10% | 305.76% | 211.73% | 112.55% | 1,384.30% | 45.27% | 54.50% | 176.31% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
627.01% | 311.92% | 108.20% | 122.06% | 71.21% | 40.05% | 471.20% | 8.64% | 12.13% | 58.45% |
Graham Net Nets |
0.22 | 0.13 | (0.02) | (0.13) | 0.11 | (0.07) | (0.19) | 0.00 | 0.10 | 0.17 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.23 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(9.20%) | (11.03%) | (12.04%) | (71.20%) | (50.57%) | (75.48%) | (34.35%) | (10.30%) | (6.31%) | (7.18%) |
Free Cash Flow Yield |
(6.28%) | (11.12%) | (2.69%) | (70.75%) | (38.00%) | (55.03%) | (26.39%) | (3.63%) | (8.88%) | (6.56%) |
Revenue per Share |
0.05 | 0.15 | 0.50 | 0.47 | 0.51 | 0.79 | 0.05 | 1.07 | 0.78 | 0.25 |
Operating CF per Share |
(1.40) | (3.16) | (0.79) | (5.56) | (2.96) | (1.72) | (1.62) | (0.18) | (1.09) | (1.11) |
Capex per Share |
(0.24) | (0.71) | (0.34) | (0.12) | (0.03) | (0.01) | (0.02) | (0.01) | (0.01) | 0.00 |
Free Cash Flow per Share |
(1.64) | (3.87) | (1.13) | (5.67) | (2.99) | (1.73) | (1.64) | (0.19) | (1.10) | (1.12) |
Cash per Share |
6.59 | 5.37 | 6.03 | 4.35 | 4.70 | 2.91 | 1.12 | 1.89 | 2.18 | 3.57 |
Shareholders Equity per Share |
6.26 | 5.56 | 2.53 | 1.88 | 2.11 | 0.63 | (0.57) | 0.37 | 1.52 | 3.07 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.26 | 5.56 | 2.53 | 1.88 | 2.11 | 0.63 | (0.57) | 0.37 | 1.52 | 3.07 |
Free Cash Flow |
(37.49) | (102.56) | (32.80) | (192.15) | (117.32) | (89.55) | (129.04) | (20.55) | (151.96) | (188.21) |
Working Capital |
139.84 | 132.30 | 72.23 | 67.32 | 109.00 | 98.36 | 27.02 | 48.93 | 209.44 | 519.75 |
Capital Expenditures |
(5.56) | (18.89) | (9.94) | (3.92) | (1.34) | (0.56) | (1.25) | (1.11) | (0.94) | (0.72) |
Net Current Asset Value |
129.92 | 116.13 | (20.32) | (35.04) | 33.58 | (11.94) | (92.94) | 0.05 | 177.70 | 494.67 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
5.09 | 4.85 | 0.69 | 0.25 | 0.07 | 0.01 | 0.34 | 0.01 | 0.01 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.09 | 0.07 | 0.12 | 0.25 | 0.34 | 0.44 | 0.59 | 0.70 | 0.86 | 1.20 |
Cash ROIC |
(12.79%) | (35.37%) | (13.22%) | (91.11%) | (43.89%) | (48.92%) | (297.28%) | (8.56%) | (29.70%) | (16.80%) |
Accounts Receivable Turnover |
0.00 | 6.49 | 2.62 | 1.07 | 0.80 | 0.00 | 0.00 | 4.44 | 9.62 | 31.67 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | 0.00 | — | — | — |
Average Receivables |
— | 0.60 | 5.50 | 15.00 | 25.00 | — | — | 25.54 | 11.25 | 1.35 |
Average Payables |
3.88 | 6.27 | 10.34 | 11.08 | 11.43 | 10.54 | 12.10 | 14.88 | 14.55 | 15.98 |
Average Assets |
165.12 | 173.33 | 238.89 | 290.10 | 281.74 | 243.12 | 176.70 | 210.67 | 313.58 | 495.35 |
Average Common Equity |
144.18 | 137.24 | 106.48 | 68.54 | 73.26 | 57.64 | (6.30) | (2.73) | 124.57 | 363.94 |
Columns are period end dates